Clinical Trial Update: Study of HBV-TCR T Cells (LioCyx-M) as Monotherapy or as Combination With Lenvatinib for HBV-related HCC [Phase 2]

View source ↗

Summary

Phase 2 study of HBV-TCR T Cells (LioCyx-M) as monotherapy or with Lenvatinib for HBV-related hepatocellular carcinoma; the trial is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• HBV-TCR T Cells (LioCyx-M) (HBV-TCR T Cells)
• Lenvatinib (lenvatinib)

Snippet

Sponsor: Lion TCR Pte. Ltd. | Conditions: Hepatocellular Carcinoma, Liver Cancer, Adult | Phase 2 | Status: NOT_YET_RECRUITING